Paroxetine Hydrochloride — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	1-2 mg/kg	q24h	Duration: Long-term (weeks to months) Notes: Start at lower end and titrate gradually. Clinical response may take 2-4 weeks.
Cat	PO	0.5-1 mg/kg	q24h	Duration: Long-term (weeks to months) Notes: Cats may be more sensitive; use lower starting dose. Titrate slowly.
Horse	PO	0.1-0.5 mg/kg	q24h	Duration: Long-term Notes: Limited data; use with caution and monitor for adverse effects.
Rabbit	PO	0.5-1 mg/kg	q24h	Duration: Long-term Notes: Limited data; use with caution.

Clinical Indications & Species Uses

General Indications

Behavioral disorders in companion animals

Dog (Canine)

Separation anxiety
Compulsive disorders (e.g., tail chasing, flank sucking)
Generalized anxiety
Aggression (as adjunct to behavior modification)
Panic disorders

Cat (Feline)

Urine spraying (marking)
Compulsive disorders (e.g., overgrooming)
Anxiety-related disorders
Aggression (as adjunct to behavior modification)

Pharmacology & Mechanism of Action

Drug Class: Selective Serotonin Reuptake Inhibitor (SSRI) | Pharmacological Group: Antidepressant

Mechanism of Action: Paroxetine is a selective serotonin reuptake inhibitor that blocks the reuptake of serotonin (5-HT) at the presynaptic neuronal membrane, thereby increasing the concentration of serotonin in the synaptic cleft. This enhances serotonergic neurotransmission. It has minimal affinity for other receptors such as alpha-adrenergic, histaminergic, or muscarinic receptors, but it does have weak anticholinergic effects at higher doses.

Pharmacodynamics: Paroxetine potentiates serotonergic activity in the central nervous system, which is thought to underlie its antidepressant and anxiolytic effects. It also has some noradrenergic and dopaminergic effects at higher doses. In veterinary medicine, it is used for behavioral disorders such as separation anxiety, compulsive behaviors, and aggression. The onset of therapeutic effect is typically 2-4 weeks.

⚡ Pharmacokinetics Summary

Absorption: Paroxetine is well absorbed after oral administration. Peak plasma concentrations occur within 2-8 hours in dogs. Food may slightly delay absorption but does not significantly affect overall bioavailability.

Distribution: Paroxetine is widely distributed in the body. It is highly lipophilic and has a large volume of distribution. It crosses the blood-brain barrier and placenta, and is excreted in milk.

Metabolism: Paroxetine undergoes extensive hepatic metabolism primarily via cytochrome P450 enzymes, particularly CYP2D6 in humans. In dogs, similar pathways are involved. It undergoes first-pass metabolism, resulting in lower systemic bioavailability compared to the administered dose.

Excretion: Metabolites are excreted primarily in urine (about 64%) and feces (about 36%). A small amount of the drug is excreted unchanged in urine.

Half-Life: Dogs: approximately 6-8 hours; Cats: approximately 8-12 hours (estimated); Horses: not well documented.

Bioavailability: Oral bioavailability is approximately 50-60% in dogs due to first-pass metabolism.

Protein Binding: Approximately 93-95% bound to plasma proteins in humans; similar in animals.

Available Formulations & Strengths

Oral Tablet 10 mg, 20 mg, 30 mg, 40 mg (PO)

Oral Suspension 10 mg/5 mL (PO)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to paroxetine or any component of the formulation
Concurrent use with MAO inhibitors (e.g., selegiline, amitraz) - risk of serotonin syndrome
Use within 14 days of MAO inhibitor therapy
Severe hepatic or renal impairment (use with caution)
History of seizures (may lower seizure threshold)

Warnings & Clinical Precautions:

Use with caution in patients with cardiovascular disease, as SSRIs may cause QT prolongation.
May cause behavioral changes; monitor for increased anxiety or agitation.
Do not discontinue abruptly; taper dose to avoid withdrawal symptoms.
Use with caution in geriatric patients; may be more sensitive to adverse effects.
In cats, may cause anorexia and weight loss; monitor food intake.
Safety in pregnant or lactating animals has not been established; use only if clearly needed.
May interact with other serotonergic drugs (e.g., tramadol, buspirone) - risk of serotonin syndrome.

Adverse Effects & Reactions

Common:

Gastrointestinal upset (vomiting, diarrhea, decreased appetite)
Lethargy or sedation
Behavioral changes (e.g., increased anxiety, agitation)
Mydriasis (pupil dilation)

Serious / Severe:

Serotonin syndrome (hyperthermia, tremors, agitation, seizures)
QT prolongation and cardiac arrhythmias
Hepatotoxicity (rare)
Seizures (especially in epileptic patients)

Rare:

Hypersensitivity reactions (rash, urticaria)
Blood dyscrasias (thrombocytopenia, leukopenia)
Hyponatremia (SIADH)

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
MAO inhibitors (e.g., selegiline, amitraz)	Severe serotonin syndrome (hyperthermia, tremors, seizures) - contraindicated.	High
Other SSRIs or SNRIs (e.g., fluoxetine, venlafaxine)	Additive serotonergic effects, increased risk of serotonin syndrome.	High
Tramadol	Additive serotonergic effects, risk of serotonin syndrome.	Moderate
Buspirone	Additive serotonergic effects, risk of serotonin syndrome.	Moderate
NSAIDs (e.g., carprofen, meloxicam)	Increased risk of gastrointestinal bleeding due to platelet inhibition.	Moderate
Drugs metabolized by CYP2D6 (e.g., metoprolol, codeine)	Paroxetine inhibits CYP2D6, increasing levels of these drugs.	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Vomiting
Lethargy
Ataxia
Tremors
Seizures
Hyperthermia
Mydriasis
Tachycardia
Serotonin syndrome (agitation, muscle rigidity, hyperthermia)

Emergency Treatment Protocol: Induce vomiting if recent ingestion and patient is stable. Administer activated charcoal to reduce absorption. Provide symptomatic and supportive care: IV fluids, temperature management, anticonvulsants (e.g., diazepam) for seizures, and cyproheptadine (serotonin antagonist) for serotonin syndrome. Monitor cardiac function and electrolytes. Hospitalization may be required.

Food Animal Withdrawal Times

Not approved for food animals; no withdrawal times established. Use in food animals is prohibited.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F).

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light and moisture. Keep in a tightly closed container.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; used extra-label in companion animals.

Extra-Label (Off-Label) Use: In the US, extra-label use in animals is permitted under AMDUCA (Animal Medicinal Drug Use Clarification Act) for non-food animals only. Use in food animals is prohibited due to lack of withdrawal times and potential human food safety concerns.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Paroxetine is a potent SSRI used in veterinary medicine primarily for behavioral disorders in dogs and cats. It is not FDA-approved for veterinary use, so it is used extra-label. Clinical response may take several weeks; therefore, it is important to inform owners of the delayed onset. Dosing should be individualized, and gradual titration is recommended to minimize adverse effects. Abrupt discontinuation should be avoided to prevent withdrawal-like signs. Monitoring for serotonin syndrome is essential, especially when used concurrently with other serotonergic drugs. In cats, appetite suppression is a common side effect; weight and food intake should be monitored. Paroxetine should be used as part of a comprehensive behavior modification plan, not as a sole treatment.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)